{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:20:33Z","timestamp":1781677233705,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Comprehensive population-based data on myeloid neoplasms (MNs) are limited, mainly because some subtypes were not recognized as hematological cancers prior to the WHO publication in 2001, and others are too rare to allow robust estimates within regional studies. Herein, we provide incidence data of the whole spectrum of MNs in Spain during 2002\u20132013 using harmonized data from 13 population-based cancer registries. Cases (<jats:italic>n<\/jats:italic>\u2009=\u200917,522) were grouped following the HAEMACARE groupings and 2013-European standardized incidence rates (ASR<jats:sub>E<\/jats:sub>), incidence trends, and estimates for 2021 were calculated. ASR<jats:sub>E<\/jats:sub> per 100,000 inhabitants was 5.14 (95% CI: 5.00\u20135.27) for myeloproliferative neoplasms (MPN), 4.71 (95% CI: 4.59\u20134.84) for myelodysplastic syndromes (MDS), 3.91 (95% CI: 3.79\u20134.02) for acute myeloid leukemia, 0.83 (95% CI: 0.78\u20130.88) for MDS\/MPN, 0.35 (95% CI: 0.32\u20130.39) for acute leukemia of ambiguous lineage, and 0.58 (95% CI: 0.53\u20130.62) for not-otherwise specified (NOS) cases. This study highlights some useful points for public health authorities, such as the remarkable variability in incidence rates among Spanish provinces, the increasing incidence of MPN, MDS, and MDS\/MPN during the period of study, in contrast to a drop in NOS cases, and the number of cases expected in 2021 based on these data (8446 new MNs).<\/jats:p>","DOI":"10.1038\/s41598-021-03734-6","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T11:04:32Z","timestamp":1641812672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Incidence of myeloid neoplasms in Spain (2002\u20132013): a population-based study of the Spanish network of cancer registries"],"prefix":"10.1038","volume":"12","author":[{"given":"Marta","family":"Solans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza","family":"Sanvisens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ameijide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"Alem\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Banqueri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Chico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visitaci\u00f3n","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza L\u00f3pez","family":"de Munain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Puigdemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jos\u00e9","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Perucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ruiz-Armengol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00aa Dolores","family":"Chirlaque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e0","family":"Carulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Marcos-Gragera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"3734_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA. Cancer J. Clin."},{"key":"3734_CR2","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant, M. et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116, 3724\u20133734 (2010).","journal-title":"Blood"},{"key":"3734_CR3","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"ES Jaffe","year":"2001","unstructured":"Jaffe, E. S., Harris, N. L., Stein, H. & Wardiman, J. W. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC Press, 2001)."},{"key":"3734_CR4","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow, S. H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC Press, 2008)."},{"key":"3734_CR5","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow, S. H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC Press, 2017)."},{"key":"3734_CR6","unstructured":"Sant, M., Karjalainen-Lindsberg, M. L., Maynadi\u00e9, M., & HAEMACARE Working Group. Manual for coding and reporting haematological malignancies. Tumori 96(4), (2010)."},{"key":"3734_CR7","first-page":"357","volume-title":"International Classification of Diseases for Oncology","author":"A Fritz","year":"2000","unstructured":"Fritz, A. et al. International Classification of Diseases for Oncology 3rd edn, 357 (World Health Organization, 2000).","edition":"3"},{"key":"3734_CR8","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","volume":"48","author":"O Visser","year":"2012","unstructured":"Visser, O. et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur. J. Cancer 48, 3257\u20133266 (2012).","journal-title":"Eur. J. Cancer"},{"key":"3734_CR9","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjh.14061","volume":"174","author":"SA Srour","year":"2016","unstructured":"Srour, S. A. et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001\u201312. Br. J. Haematol. 174, 382\u2013396 (2016).","journal-title":"Br. J. Haematol."},{"key":"3734_CR10","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/cncr.22570","volume":"109","author":"X Ma","year":"2007","unstructured":"Ma, X., Does, M., Raza, A. & Mayne, S. T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109, 1536\u20131542 (2007).","journal-title":"Cancer"},{"key":"3734_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","volume":"112","author":"DE Rollison","year":"2008","unstructured":"Rollison, D. E. et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs. Blood 112, 45\u201352 (2008).","journal-title":"Blood"},{"key":"3734_CR12","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1002\/cncr.31674","volume":"124","author":"C Bailey","year":"2018","unstructured":"Bailey, C. et al. Adult leukemia survival trends in the United States by subtype: a population-based registry study of 370,994 patients diagnosed during 1995\u20132009. Cancer 124, 3856\u20133867 (2018).","journal-title":"Cancer"},{"key":"3734_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3324\/haematol.2010.026252","volume":"96","author":"M Maynadi\u00e9","year":"2011","unstructured":"Maynadi\u00e9, M. et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d\u2019Or (Burgundy, France). Haematologica 96, 55\u201361 (2011).","journal-title":"Haematologica"},{"key":"3734_CR14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","volume":"42","author":"E Roman","year":"2016","unstructured":"Roman, E. et al. Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK\u2019s population-based Haematological Malignancy Research Network 2004\u201315. Cancer Epidemiol. 42, 186\u2013198 (2016).","journal-title":"Cancer Epidemiol."},{"key":"3734_CR15","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.3324\/haematol.2013.084061","volume":"98","author":"G Osca-Gelis","year":"2013","unstructured":"Osca-Gelis, G. et al. Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. Haematologica 98, e95\u2013e97 (2013).","journal-title":"Haematologica"},{"key":"3734_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/annonc\/mdq094","volume":"21","author":"C Navarro","year":"2010","unstructured":"Navarro, C. et al. Population-based cancer registries in Spain and their role in cancer control. Ann. Oncol. 21, 3\u201313 (2010).","journal-title":"Ann. Oncol."},{"key":"3734_CR17","unstructured":"Spanish Network of Cancer Registries (REDECAN). Available at: https:\/\/stage.redecan.org\/es. (Accessed: 17th March 2021)"},{"key":"3734_CR18","unstructured":"Instituto Nacional de Estad\u00edstica (INE) [Available at: https:\/\/www.ine.es, last accessed on April 16, 2020]."},{"key":"3734_CR19","unstructured":"World Health Organization. International classification of diseases for oncology (ICD-O) \u2013 3rd edition, 1st revision, 3rd ed.; 2013. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/96612."},{"key":"3734_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3324\/haematol.2012.064014","volume":"98","author":"M Maynadi\u00e9","year":"2013","unstructured":"Maynadi\u00e9, M. et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica 98, 230\u2013238 (2013).","journal-title":"Haematologica"},{"key":"3734_CR21","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.ejca.2014.02.008","volume":"51","author":"A Gavin","year":"2015","unstructured":"Gavin, A. et al. Towards optimal clinical and epidemiological registration of haematological malignancies: Guidelines for recording progressions, transformations and multiple diagnoses. Eur. J. Cancer 51, 1109\u20131122 (2015).","journal-title":"Eur. J. Cancer"},{"key":"3734_CR22","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2020. Available at: https:\/\/www.R-project.org\/."},{"key":"3734_CR23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3324\/haematol.2010.034264","volume":"96","author":"R Marcos-Gragera","year":"2011","unstructured":"Marcos-Gragera, R. et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000\u20132002: Results of the HAEMACARE project. Haematologica 96, 720\u2013728 (2011).","journal-title":"Haematologica"},{"key":"3734_CR24","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter, E. J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054\u20131061 (2005).","journal-title":"Lancet"},{"key":"3734_CR25","first-page":"77","volume":"41","author":"AP Polednak","year":"2014","unstructured":"Polednak, A. P. Recent improvement in completeness of incidence data on acute myeloid leukemia in US cancer registries. J. Registry Manag. 41, 77\u201384 (2014).","journal-title":"J. Registry Manag."},{"key":"3734_CR26","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1182\/blood-2008-09-179341","volume":"113","author":"\u00c5R Derolf","year":"2009","unstructured":"Derolf, \u00c5. R. et al. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 113, 3666\u20133672 (2009).","journal-title":"Blood"},{"key":"3734_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/hon.733","volume":"22","author":"G Broccia","year":"2004","unstructured":"Broccia, G. et al. Hematological malignancies in the island of Sardinia, 1974\u20131993: age and sex distributions and temporal changes in incidence. Hematol. Oncol. 22, 91\u2013109 (2004).","journal-title":"Hematol. Oncol."},{"key":"3734_CR28","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith, A., Howell, D., Patmore, R., Jack, A. & Roman, E. Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br. J. Cancer 105, 1684\u20131692 (2011).","journal-title":"Br. J. Cancer"},{"key":"3734_CR29","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/cncr.32034","volume":"125","author":"FM Ghazawi","year":"2019","unstructured":"Ghazawi, F. M. et al. Analysis of acute myeloid leukemia incidence and geographic distribution in Canada from 1992 to 2010 reveals disease clusters in Sarnia and other industrial US border cities in Ontario. Cancer 125, 1886\u20131897 (2019).","journal-title":"Cancer"},{"key":"3734_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.canep.2017.11.008","volume":"52","author":"A Schnegg-Kaufmann","year":"2018","unstructured":"Schnegg-Kaufmann, A. et al. Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. Cancer Epidemiol. 52, 55\u201362 (2018).","journal-title":"Cancer Epidemiol."},{"key":"3734_CR31","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/sj.leu.2404055","volume":"20","author":"RN Sanderson","year":"2006","unstructured":"Sanderson, R. N. et al. Population-based demographic study of karyotypes in 1709 patients with adult Acute Myeloid Leukemia. Leukemia 20, 444\u2013450 (2006).","journal-title":"Leukemia"},{"key":"3734_CR32","first-page":"1502","volume":"90","author":"U Bacher","year":"2005","unstructured":"Bacher, U. et al. Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica 90, 1502\u20131510 (2005).","journal-title":"Haematologica"},{"key":"3734_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1046\/j.1365-2141.2003.04568.x","volume":"123","author":"BS Preiss","year":"2003","unstructured":"Preiss, B. S. et al. Cytogenetic findings in adult de novo acute myeloid leukaemia. A population-based study of 303\/337 patients. Br. J. Haematol. 123, 219\u2013234 (2003).","journal-title":"Br. J. Haematol."},{"key":"3734_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.21037\/sci.2019.10.03","volume":"6","author":"AG Dinmohamed","year":"2019","unstructured":"Dinmohamed, A. G. & Visser, O. Incidence of acute promyelocytic leukemia across Europe: results of RARECAREnet-a population-based study. Stem cell Investig. 6, 37 (2019).","journal-title":"Stem cell Investig."},{"key":"3734_CR35","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2008.004234","volume":"94","author":"F Girodon","year":"2009","unstructured":"Girodon, F. et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Haematologica 94, 865\u2013869 (2009).","journal-title":"Haematologica"},{"key":"3734_CR36","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41375-018-0314-7","volume":"33","author":"AMJ Reedijk","year":"2019","unstructured":"Reedijk, A. M. J. et al. Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. Leukemia 33, 1349\u20131359 (2019).","journal-title":"Leukemia"},{"key":"3734_CR37","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"},{"key":"3734_CR38","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1158\/1055-9965.EPI-19-0106","volume":"28","author":"MR Sweeney","year":"2019","unstructured":"Sweeney, M. R. et al. Medical conditions and modifiable risk factors for myelodysplastic syndrome: a systematic review. Cancer Epidemiol. Biomarkers Prev. 28, 1502\u20131517 (2019).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"3734_CR39","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1097\/HS9.0000000000000327","volume":"4","author":"AS Duncombe","year":"2020","unstructured":"Duncombe, A. S. et al. Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms. HemaSphere 4, e327 (2020).","journal-title":"HemaSphere"},{"key":"3734_CR40","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","volume":"130","author":"J Taylor","year":"2017","unstructured":"Taylor, J., Xiao, W. & Abdel-Wahab, O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood 130, 410\u2013423 (2017).","journal-title":"Blood"},{"key":"3734_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1158\/1055-9965.EPI-11-1087","volume":"21","author":"BM Craig","year":"2012","unstructured":"Craig, B. M., Rollison, D. E., List, A. F. & Cogle, C. R. Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol. Biomarkers Prev. 21, 474\u2013481 (2012).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"3734_CR42","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","volume":"117","author":"CR Cogle","year":"2011","unstructured":"Cogle, C. R., Craig, B. M., Rollison, D. E. & List, A. F. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 117, 7121\u20137125 (2011).","journal-title":"Blood"},{"key":"3734_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.leukres.2014.11.025","volume":"39","author":"AG Dinmohamed","year":"2015","unstructured":"Dinmohamed, A. G. et al. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. Leuk. Res. 39, 177\u2013182 (2015).","journal-title":"Leuk. Res."},{"key":"3734_CR44","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1002\/cncr.28641","volume":"120","author":"ZK McQuilten","year":"2014","unstructured":"McQuilten, Z. K. et al. Underestimation of myelodysplastic syndrome incidence by cancer registries: results from a population-based data linkage study. Cancer 120, 1686\u20131694 (2014).","journal-title":"Cancer"},{"key":"3734_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10552-018-1004-5","volume":"29","author":"M Solans","year":"2018","unstructured":"Solans, M. et al. Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16 years of epidemiological data from the province of Girona, Spain. Cancer Causes Control 29, 379\u2013382 (2018).","journal-title":"Cancer Causes Control"},{"key":"3734_CR46","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1002\/ijc.27889","volume":"132","author":"A Monnereau","year":"2013","unstructured":"Monnereau, A. et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int. J. cancer 132, 2378\u20132387 (2013).","journal-title":"Int. J. cancer"},{"key":"3734_CR47","unstructured":"International Agency for Cancer Registration (IACR). International Classification of Diseases for Oncology. ICD-O-3.2. (2021). Available at: http:\/\/www.iacr.com.fr\/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577. (Accessed: 3rd March 2021)."},{"key":"3734_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu, B., Guo, H., Zhou, P. & Shi, Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141\u2013154 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"3734_CR49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.medcli.2020.04.011","volume":"155","author":"D Petrova","year":"2020","unstructured":"Petrova, D., P\u00e9rez-G\u00f3mez, B., Poll\u00e1n, M. & S\u00e1nchez, M.-J. Implications of the COVID-19 pandemic for cancer in Spain. Med. Clin. (Barc) 155, 263\u2013266 (2020).","journal-title":"Med. Clin. (Barc)"},{"key":"3734_CR50","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(20)30388-0","volume":"21","author":"C Maringe","year":"2020","unstructured":"Maringe, C. et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 21, 1023\u20131034 (2020).","journal-title":"Lancet Oncol."},{"key":"3734_CR51","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11899-012-0140-3","volume":"7","author":"DP Steensma","year":"2012","unstructured":"Steensma, D. P. Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Curr. Hematol. Malig. Rep. 7, 310\u2013320 (2012).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"3734_CR52","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3324\/haematol.2011.056879","volume":"97","author":"S Parmentier","year":"2012","unstructured":"Parmentier, S. et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Haematologica 97, 723\u2013730 (2012).","journal-title":"Haematologica"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03734-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T19:49:35Z","timestamp":1669319375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03734-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3734"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03734-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"323"}}